Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

Piper Sandler analyst Adam Maeder maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Growth Strategy” third-quarter 2024 ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday. Despite the robust preliminary results, the company’s shares plunged nearly ...

Inspire Medical Systems shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to ...

Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...

Inspire Medical (TASE: PMCN )'s fourth quarter revenue represents a roughly 25% increase compared to the same quarter of the previous year, while the anticipated full-year 2024 revenue of $802.6 ...

To fuel our continued growth and advance the adoption of Inspire therapy, the Company implemented the following organizational changes: Finally, Dr. Charisse Sparks, Chief Medical Officer ...

Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”, or the "Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday.

MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company ...